US 11,814,413 B2
Compositions comprising modified HIV envelopes
Barton F. Haynes, Durham, NC (US); David Montefiori, Durham, NC (US); Kevin J. Wiehe, Durham, NC (US); Kevin O. Saunders, Durham, NC (US); and Celia C. Labranche, Durham, NC (US)
Assigned to DUKE UNIVERSITY, Durham, NC (US)
Appl. No. 16/615,768
Filed by Duke University, Durham, NC (US)
PCT Filed May 25, 2018, PCT No. PCT/US2018/034772
§ 371(c)(1), (2) Date Nov. 21, 2019,
PCT Pub. No. WO2018/218225, PCT Pub. Date Nov. 29, 2018.
Claims priority of provisional application 62/565,952, filed on Sep. 29, 2017.
Claims priority of provisional application 62/511,226, filed on May 25, 2017.
Prior Publication US 2023/0140293 A1, May 4, 2023
Int. Cl. A61K 39/21 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); C07K 14/005 (2006.01); A61P 31/18 (2006.01); C12N 7/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/21 (2013.01); A61P 31/18 (2018.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55572 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16122 (2013.01)] 20 Claims
 
1. A recombinant HIV-1 envelope polypeptide comprising HIV-1 envelope CH505 M5 with a mutation of the amino acid at position 458, wherein the HIV-1 envelope CH505 M5 polypeptide is:
a gp120 envelope comprising SEQ ID NO:424,
a gp120 delta 8 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MRVMGIQRNYPQWWIWSMLGFWMLMICNG of SEQ ID NO:407,
a gp140 envelope comprising SEQ ID NO:423,
a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.SOSIP.664v4.1_G458Y (SEQ ID NO:405),
a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.SOSIP.664v4.1 ferritin_G458Y (SEQ ID NO:408),
a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.DS.SOSIP.664(SEQ ID NO:409),
a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.SOSIP.664v5.2.8_G458Y (SEQ ID NO:410), a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.SOSIP.664v4.1avi_G458Y (SEQ ID NO:411), a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.SOSIP.664v4.1.1_G458Y (SEQ ID NO:412),
a gp140 envelope comprising the amino acid sequence of CH505M5chim.6R.SOSIP.664_G458Y (SEQ ID NO:426),
a gp140 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MPMGSLQPLATLYLLGMLVASVLA of CH505M5chim.6R.SOSIP.664v4.2 (SEQ ID NO:243),
a gp145 envelope comprising all the consecutive amino acids immediately after the signal peptide sequence MRVMGIQRNYPQWWIWSMLGFWMLMICNG of SEQ ID NO:187, or
a gp160 envelope comprising SEQ ID NO:422;
wherein the amino acid at position 458 is a tyrosine (Y), a phenylalanine (F), a tryptophan (W), an arginine (R), a cysteine (C), a leucine (L), a lysine (K), a serine (S), an aspartic acid (D), a glutamic acid (E), a methionine (M), a glutamine (Q), a histidine (H), or an asparagine (N).